FONT-SIZE Plus   Neg

FDA Accepts Impax Pharma NDA Filing For IPX066 - Quick Facts

Impax Laboratories, Inc.'s (IPXL) branded products division, Impax Pharmaceuticals, said the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application, or NDA, for IPX066 for the treatment of idiopathic Parkinson's disease submitted to the Agency on December 21, 2011. The Prescription Drug User Fee Date for a decision by the FDA is October 21, 2012.

IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

The NDA included data from three controlled Phase III studies and two open label extensions of IPX066 in both early and advanced Parkinson's disease.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Microsoft Corp. (MSFT) Tuesday unveiled two new smartphones that run on its Windows 10 operating platform, as the software giant strives to revive its beleaguered smartphone business. The Lumia 950 and 950 XL are the first smartphones phones to run on Windows 10. Microsoft hopes that millions... General Mills Inc. (GIS) is voluntarily recalling 1.8 million boxes of "gluten-free" Cheerios and Honey Nut Cheerios manufactured at its Lodi, California facility, as it may contain wheat. Wheat was inadvertently mixed into the gluten free oat flour at its facility in Lodi, California. As a result,... Microsoft (MSFT) has unveiled its latest tablet. The technology giant officially debuted the new Surface Pro 4 at its Windows 10 event, held in New York City on Tuesday. The product, meant to draw customers away from laptops, includes a 12.3 inch screen, with a smaller bezel than its Pro 3 predecessor.
comments powered by Disqus
Trade IPXL now with 
Follow RTT